13-valent pneumococcal conjugate vaccine + 23-valent pneumococcal polysaccharide vaccine

This drug entry refers to a sequential prime-boost vaccination regimen consisting of the 13-valent pneumococcal conjugate vaccine (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23). PCV13 (Prevenar 13) contains capsular polysaccharides from 13 Streptococcus pneumoniae serotypes conjugated to the CRM197 carrier protein, which induces a T-cell dependent immune response, promoting immunological memory and mucosal immunity. PPSV23 (Pneumovax 23) contains purified capsular polysaccharides from 23 serotypes, providing broader coverage through a T-cell independent mechanism. This sequential administration is evaluated in clinical trials, such as the MENPI study led by Thomas Benfield, to enhance the breadth and durability of protection against invasive pneumococcal disease in high-risk populations, including adults living with HIV.

Brand names

Prevenar 13Prevenar13Prevenar-13Pneumovax 23Pneumovax23Pneumovax-23

Other names

Prevenar 13 + Pneumovax 2313-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccinePCV13 and PPSV23 prime-boost regimenPCV-13 and PPSV23 prime-boost regimenPCV 13 and PPSV23 prime-boost regimen